Thirteen 2-oxazine-based small molecules were synthesized targeting 5-lipoxygenase (LOX), and acetylcholinesterase (AChE). The test revealed that the newly synthesized compounds had potent inhibition towards both 5-LOX and AChE in lower micro molar concentration. Among the tested compounds, the most active compound, 2-[(2-acetyl-6,6-dimethyl-4-phenyl-5,6-dihydro-2H-1,2-oxazin-3-yl)methyl]-1H-isoindole-1,3(2H)-dione (2a) showed inhibitory activity towards 5-LOX and AChE with an IC 50 values of 1.88, and 2.5 lM, respectively. Further, the in silico molecular docking studies revealed that the compound 2a bound to the catalytic domain of AChE strongly with a highest CDOCKER score of À1.18 kcal/mol when compared to other compounds of the same series. Additionally, 2a showed a good lipophilicity (log P = 2.66), suggesting a potential ability to penetrate the blood-brain-barrier. These initial pharmacological data revealed that the compound 2a could serve as a drug-seed in developing anti-Alzheimer's agents.
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Alzheimer's disease (AD) is a progressive age related neurodegenerative disorder and it is clinically characterized by impairment in memory, visuospatial skills, complex cognition, language, emotion and personality. Although the exact cause of AD remains elusive, mounting evidence continues to support the involvement of inflammation in the development of AD. 1 An inflammatory marker, interleukin-1 known to play a major role in enhancing the neuronal acetylcholinesterase (AChE) activity. [2] [3] [4] These physiological mechanism or systemic inflammation process is termed 'cholinergic anti-inflammatory pathway' because is mediated by the neurotransmitter acetylcholine (ACh). 5 Based on the compelling evidence that inflammatory processes are involved in the pathogenesis of AD, research has looked into the use of antiinflammatory drugs as a treatment option for patients with AD. Epidemiological evidence continues to build up indicating that non-steroidal anti-inflammatory drugs (NSAIDs) may lower the risk of developing AD. 6 A possible mode of action for the effectiveness of NSAIDs is by the blockage of cyclooxygenase (COX)-2 in the brain. [7] [8] [9] [10] Evidently, it has been shown that COX-2 mRNA and protein are considerably up-regulated in affected areas of AD brain, [11] [12] [13] suggesting the involvement of COX-2 in AD. So, we herein attempted to design and synthesize, 1,2-oxazine-based small molecules that could show anti-inflammatory activity and also play a major role in inhibiting the AChE activity that involved in AD. Since the discovery of 2-amino-1,3-oxazine scaffold was identified as the selective and better inhibitors of b-site amyloid precursor protein cleaving enzyme 1, and also projected to be the suitable starting point for further development of brain penetrating compounds for potential Alzheimer's disease treatment. 14 In addition, the neuroprotective effect of 2-ethoxy-4,5-diphenyl-1,3-oxazine-6-one against H 2 O 2 -induced cell death in rat pheochromocytoma cells was reported. 15 Evidently, the design, synthesis and results on 1, 4-oxazines revealed that the oxazine-based small molecules significantly inhibited the transthyretin (TTR) amyloid fibril formation. 16 In continuation of our effort to synthesize novel anti-inflammatory 17 and anti-cholinergic agents, 18 we herein report the synthesis, characterization, anti-inflammatory and anti-cholinergic activity of novel 1,2-oxazine-based small molecules for the first time.
A library of racemic tetrasubstituted functionalized 1,2-oxazines (5,6-dihydro-4H-1,2-oxazines 1 and N-acetyl-5,6-dihydro-2H-1, 2-oxazines 2) required for the biological assays was generated according to the synthetic strategy previously developed by us 19, 20 (Scheme 1, Table 1 ). Stereoselective assembly of 1,2-oxazine core was achieved by inverse electron demand Diels-Alder (IED-DA) reaction of nitroalkenes derived from nitroethane to olefines. The resulting diastereomerically pure 1,2-oxazine-N-oxides 3 were subjected to silylation with an excess of trimethylsilyl bromide in the presence of Et 3 N to give 3-bromomethyl-substituted 5,6-dihydro-4H-1,2-oxazines 4, which serve as key precursors for the synthesis of C-3 functionalized 1,2-oxazines 1 and 2. Thus, nucleophilic substitution of bromide for phthalimide or dimethylmalonate anions furnished 1,2-oxazines 1a-f. 1,2-Oxazines 1g-i with FG = CO 2 CH 3 were obtained by catalytic carbonylation of corresponding bromides 3 in methanol being followed our previously reported protocol. 21 Transformation of 5,6-dihydro-4H-1,2-oxazines 1 into and N-acetyl-5,6-dihydro-2H-1,2-oxazines 2 was achieved by acetylation of the former with AcBr/Ac 2 O mixture in high yields (Scheme 1). All compounds were obtained in analytically pure form by column chromatography on silica gel and crystallization. The structure and stereochemistry of previously unknown products was confirmed by 1D and 2D NMR spectroscopy and elemental analysis.
Effect of 2-oxazines on LOX-5 and AChE. Oxazin-2-thione-based small molecule exhibited LOX and COX-1 inhibitory action. 22 In particular, 5-LOX catalyses the biosynthesis of leukotrienes play a pivotal role in inflammatory and allergic disorders as well as in cardiovascular diseases and cancer. 23 Additionally, tetrahydro-1,4- oxazines are known to be biologically active against inflammatory drug metabolizing enzymes. 24 The potential of all the synthesized compounds to inhibit 5-LOX and AChE was determined on pure enzymes. Since inflammation occurs in the pathological regions of Alzheimer's disease (AD) brain, and a few animal models and clinical studies clearly suggest that AD inflammation significantly contributes to AD pathogenesis. 1 Some of the tested 1,2-oxazines exhibited 5-LOX inhibitory activity, with the exception of 1f, 1g, and 2d. Amongst the new compounds 2a, 2b, and 2c exhibited most potent 5-LOX inhibitory activities, whereas compounds 2a and 1i were found to inhibit the activity of AChE (Table 3) effectively. Interestingly, the most active compound 2a showed inhibitory activity towards both the enzymes 5-LOX and AChE with an IC 50 values of 1.88, and 2.5 lM, respectively. These results indicated that the 1,2-oxazine pharmacophore plays an important role in deciding the preferences for these enzyme sites. The present work thus confirms that the 1,2-oxazine-based ligands are effective LOX/AChE inhibitors, which can serve as promising therapeutic agents against Alzheimer disease. Structure based in silico molecular docking analysis on 1,2-oxazine-based small molecules that target AChE. Many cholinesterase inhibitors are used for symptomatic treatment of AD. 25 The drug, Aricept (E2020) was known to enhance performance in animal models of cholinergic hypofunction and has a high affinity for AChE. 26 Prior to the elucidation of three-dimensional structure of Torpedo californica AChE (TcAChE), E2020 was designed on the basis of QSAR studies, which inhibited both electric eel and mouse AChE in the nanomolar range. Later, the co-crystal structure of the E2020-TcAChE complex at 2.5 Å resolution (PDB ID: 1EVE) was reported. This structure was taken for our molecular docking studies. 26 The molecular docking studies on 1,2-oxazine-based small molecules into the crystal structure of tcAChE were performed using CDOCKER of Accelrys as reported earlier. 27 Out of 10 docked complexes, the high score of CDOCKER energy was selected and described (Table 3 ). The analysis of the molecular docking revealed that the compound 1i, and 2a bound to the active site of the tcAChE with a greater extent of CDOCKER energies of 11.8, and À1.14 (kcal/mol), when compared to other structurally compounds ( Table 2 ). E2020 that bound to the active site of AChE is compared with the 1,2-oxazines. The binding of compound 2a towards the binding of AChE is depicted in Figure 1 . The compound 2a makes primary interactions at the active-site gorge of the enzyme through its three major functional groups such as phthalamide moiety, N-acetyl-2-oxazine ring, and the phenyl rings. These functional groups responsible for three inter-hydrogen bonding formation between Tyr334, Asp72, and Asn85 amino acids, Gly118, and Ser122 amino acids, and also with Gln69, Gly123, and Tyr121 amino acids. These results indicate that the strong affinity of compound 2a on AChE could lead to the potent inhibition of the catalytic activity of the enzyme. We herein report the synthesis of new 2-oxazine-based small molecules targeting 5-LOX and AChE. Among the tested compounds, the most active compound 2a showed inhibitory activity towards 5-LOX and AChE with an IC 50 value of 1.88, and 2.5 lM, respectively. Further, the in silico molecular docking studies revealed that the compound 2a and 1e bound to the catalytic domain of AChE strongly with a highest CDOCKER score about À1.18, and 11.8 (kcal/mol), when compared to other compounds of the same series. These initial pharmacological data revealed that the compound 2a could serve as a drug-seed in developing antiAlzheimer's agents.
